Printer Friendly

SANDOZ PHARMACEUTICALS SETTLES LITIGATION

 SANDOZ PHARMACEUTICALS SETTLES LITIGATION
 EAST HANOVER, N.J., Sept. 3 /PRNewswire/ -- Sandoz Pharmaceuticals


Corporation today announced that it has settled litigation brought by the Attorneys General of 33 states, the District of Columbia and several private plaintiffs charging that Sandoz had violated antitrust laws in the distribution of CLOZARIL (R) (clozapine), the company's breakthrough treatment for schizophrenia.
 "We are confident that the distribution system for CLOZARIL therapy, in effect from February 1990 through May of 1991, which was designed to protect patients' lives, would have been found to be within the letter and spirit of the antitrust laws. And, in fact, within the settlement agreement Sandoz explicitly denies all liability in the matter," said Tim Rothwell, Sandoz president and chief executive officer.
 "We also believe, however, that a protracted dispute would limit patient access to this important therapy and, therefore, considered a speedy resolution to be within the best interests of patients and the company."
 The settlement calls for the establishment of a fund for all CLOZARIL patients who paid for and received the product from Feb. 5, 1990 through May 31, 1991 through the CLOZARIL Patient Management System. This fund will consist primarily of credits for CLOZARIL purchases. In addition, the settlement provides that Sandoz will arrange for the distribution of additional CLOZARIL to patients who may have been denied access to the drug as a result of the controversy over the monitoring system. "We are pleased that the settlement includes this distribution of CLOZARIL, because we are confident more patients will benefit from therapy," Rothwell said.
 The company noted that it changed its distribution system for CLOZARIL effective June 1, 1992. While weekly monitoring is still required to protect against the development of a fatal blood disorder associated with CLOZARIL use, it is now provided by physicians and pharmacists rather that a Sandoz - contracted supplier. This has also meant that the product is now distributed through traditional wholesalers and retail pharmacies, rather that through a single contracted monitoring company.
 -0- 9/3/92
 /CONTACT: Gil Honigfeld of Sandoz Pharmaceuticals Corporation, 201-503-8351/ CO: Sandoz Pharmaceuticals Corporation ST: New Jersey IN: MTC SU:


LR-AH -- NY045 -- 6400 09/03/92 12:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 3, 1992
Words:362
Previous Article:MARRIOTT CORPORATION IMPLEMENTS 'MARRIOTT CARES' HURRICANE ANDREW RELIEF EFFORT
Next Article:FREMONT ENTERS 10-YEAR TECHNOLOGY ALLIANCE WITH EDS
Topics:


Related Articles
SANDOZ PHARMACEUTICALS NAMES TIM ROTHWELL PRESIDENT AND CEO
STATES SETTLE ANTITRUST SUIT AGAINST SANDOZ DRUG COMPANY TO PAY $16.5 MILLION IN DAMAGES AND COSTS
PENNSYLVANIA TO BENEFIT FROM PROPOSED SETTLEMENT OF CLOZARIL CASE
SANDOZ PHARMACEUTICALS SETTLES LITIGATION
SANDOZ PHARMACEUTICALS: FREE PRESCRIPTION MEDICATION AVAILABLE TO THOSE DISPLACED BY HURRICANE ANDREW
MAGAININ PHARMACEUTICALS AND SANDOZ ANNOUNCE STRATEGIC ALLIANCE IN CANCER
MAGAININ PHARMACEUTICALS AND SANDOZ ANNOUNCE STRATEGIC ALLIANCE IN CANCER
Sandoz to Launch Generic Ceftriaxone Injection(R).
Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters